Study of Unani Formulations in Asthma
Phase 2
- Conditions
- Health Condition 1: J454- Moderate persistent asthma
- Registration Number
- CTRI/2022/03/041190
- Lead Sponsor
- ational Institute of Unani Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
•Known cases of mild to moderate Asthma
•All gender
•Age between 21 to 60 years
•Non-smoker
Exclusion Criteria
•Known cases of Acute or severe Asthma (FEV1 <60%)
(1) FEV1 < 60% of predicted in spirometry;
(2) PEF variability <40% to >30% to at least 2 times during an 1-week
monitoring period;
(3) use of short-acting bronchodilating medication at least four
times daily; and/or
(4) Daily use of oral steroid
•Subject with a History of COPD, Pneumonia, Occupational lung diseases
and pulmonary tuberculosis
•History of Smoking
•Pregnant & lactating mothers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in Spirometry parametersTimepoint: On 0, 15,30, and 45th Day
- Secondary Outcome Measures
Name Time Method Improvement in ACQTimepoint: On 0, 15,30, and 45th Day